Genalyte Signs on European Distributors as Maverick System Gains CE Mark
News Jul 25, 2013
Genalyte, Inc. has announced that its Maverick™ Detection System that simultaneously analyzes multiple antibodies and other proteins from a single small sample is now CE marked in Europe for research use.
The company also reported its first European distribution agreements for the Maverick Detection System, signing on specialty distributors Mokascience in France, Bucher Biotec in Switzerland and KRD Molecular Technologies in the Czech Republic, Slovakia and Hungary.
Genalyte’s Maverick Detection System uses a silicon chip containing arrays of photonic ring sensors that simultaneously analyze multiple antibodies and other proteins from a single small sample.
The one-step workflow of the Maverick multiplex system can deliver accurate results in as little as 15 minutes from small volume samples of many types.
The Maverick platform has a large dynamic range and excellent sensitivity with outstanding reproducibility.
“The Maverick System and our growing family of multiplex assays have generated a great deal of interest in Europe, so this CE mark designation and the appointment of our first European distributors are especially timely,” said Martin Gleeson, PhD, Chief Scientific Officer of Genalyte.
Gleeson continued, “We plan to launch several new multiplex assays in the coming months and also expect to announce additional distributor agreements as we build a distribution network to reach pharmaceutical, biotechnology and academic researchers around the globe.”
The Maverick Detection System and its ENA 4, ENA 6 and ANA 14 Assay Kits are commercially available. Assay kits for SLE, Sjogren’s syndrome and type I diabetes research are available under Genalyte’s Technology Access Program.
Additionally, Genalyte offers researchers a Custom Spotting Service that loads proteins supplied by customers, such as antibodies, peptides, biomarkers, cytokines and antigens, onto standard-format Genalyte chips that are ready to be run on the Maverick System.
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Fight Against Cancer: Drug Combination Helps Kickstart the Immune SystemNews
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together help kick start the body's natural defences.